Trial Profile
Phase I study of rifampin on the steady-state pharmacokinetics (Pk) of crizotinib in cancer patients.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 May 2016
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Rifampicin (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 02 May 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics